首页> 外文OA文献 >IMMU-05. IMMUNE STIMULATION AND IMMUNE CHECKPOINT INHIBITION PROVIDED BY A SINGLE AGENT: AN ONCOLYTIC HSV EXPRESSING A scFv ANTIBODY AGAINST PD-1

【2h】

IMMU-05. IMMUNE STIMULATION AND IMMUNE CHECKPOINT INHIBITION PROVIDED BY A SINGLE AGENT: AN ONCOLYTIC HSV EXPRESSING A scFv ANTIBODY AGAINST PD-1

机译：IMMU-05。单个试剂提供的免疫刺激和免疫检查点抑制：表达PD-1的SCFV抗体的溶溶解HSV

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Carmela Passaro; Quazim Alayo; Hiroshi Nakashima; E Antonio Chiocca;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade [J] . Eric Bartee, Zihai Li Experimental Hematology Oncology . 2017,第1期

机译：通过溶瘤药和PD-1免疫检查点阻断剂的体内和原位肿瘤免疫编程
2. 401?Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors [J] . Manish Sharma, Ecaterina Ileana Dumbrava, Richard Carvajal, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：401？第1/2期新型HER2靶向，TLR7 / 8免疫刺激抗体缀合物（ISAC）BDC-1001，具有或不具有免疫检查点抑制剂的高级HER2表达实体肿瘤
3. 421?Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors [J] . Francesca Aroldi, Joseph Sacco, Kevin Harrington, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：421？RP2的第1阶段试验的初始结果，第一类，增强效力，抗CTLA-4抗体表达，溶胶作为单一剂，与实体肿瘤患者的Nivolumab联合
4. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019

机译：免疫检查点的分子动力学程序性细胞死亡蛋白I，PD-1：配体PD-L1与单克隆抗体nivolumab结合后BC环的构象变化
5. Immune Checkpoints PD-1/PD-L1 and Natural Killer Cells in Chemo-resistant Colorectal Cancer [D] . Siu, Hon Lam Elaine. 2019

机译：免疫检查点PD-1 / PD-L1和化疗结直肠癌中的天然杀伤细胞
6. IMMU-05. IMMUNE STIMULATION AND IMMUNE CHECKPOINT INHIBITION PROVIDED BY A SINGLE AGENT: AN ONCOLYTIC HSV EXPRESSING A scFv ANTIBODY AGAINST PD-1 [O] . Carmela Passaro, Quazim Alayo, Hiroshi Nakashima, 2017

机译：IMMU-05。单剂提供的免疫刺激和免疫检查点抑制：表达PD-1的scFv抗体的溶瘤HSV
7. In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade [O] . Eric Bartee, Zihai Li 2017

机译：通过组合溶血性和PD-1免疫检查点封闭来体内和肿瘤抗扰度的原位编程

IMMU-05. IMMUNE STIMULATION AND IMMUNE CHECKPOINT INHIBITION PROVIDED BY A SINGLE AGENT: AN ONCOLYTIC HSV EXPRESSING A scFv ANTIBODY AGAINST PD-1

著录项

引文网络

相似文献

相关主题

期刊订阅